VH-4011499A is under clinical development by ViiV Healthcare and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS). According to GlobalData, Phase II drugs for Human Immunodeficiency Virus (HIV) Infections (AIDS) have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VH-4011499A’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VH-4011499A overview
VH-4011499A is under development for the treatment of human immunodeficiency virus (HIV) infections (AIDS). It acts by targeting capsid protein of HIV virus. The drug candidate is developed based on ENHANZE drug delivery technology, a recombinant human hyaluronidase PH20 enzyme (rHuPH20) technology platform. It is administered through oral, subcutaneous and intramuscular route
ViiV Healthcare overview
ViiV Healthcare (ViiV), a subsidiary of GSK plc, is a research company. It researches and develops the use of HIV medicines. The company offers nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, and CCR5 antagonists for the treatment of AIDS. Its products include dolutegravir, zidovudine, fosamprenavi, maraviroc, abacavir, and nelfinavir. ViiV also offers various fellowship programs for primary care HIV specialists. The company partners with the HIV community to provide education and support services to people with AIDS. It operates in Japan, the US, the Netherlands, the UK, Australia, Portugal, China, Switzerland, Puerto Rica and Belgium. ViiV is headquartered in Brentford, the UK.
For a complete picture of VH-4011499A’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
